BD Launches Revolutionary FACSDiscover A8 Cell Analyzer with Dual Breakthrough Technologies
• BD (Becton, Dickinson and Company) has globally launched the world's first cell analyzer combining spectral and real-time cell imaging technologies, enabling researchers to uncover previously invisible cellular insights with greater ease and throughput.
• The new BD FACSDiscover A8 Cell Analyzer features SpectralFX Technology that allows scientists to analyze up to 50 characteristics of a single cell simultaneously, and CellView Image Technology that provides high-speed fluorescent and label-free imaging of cellular structures.
• This groundbreaking instrument, alongside new software innovations including BD FACSChorus and FlowJo v11, represents a significant advancement in flow cytometry that will accelerate biomarker discovery and deepen understanding of cellular interactions across multiple research applications.
BD Initiates Pivotal STANCE Trial Testing GalaFLEX LITE Scaffold for Reducing Capsular Contracture in Breast Implant Revision Surgery
• BD (Becton, Dickinson and Company) has treated the first patient in its STANCE clinical trial, evaluating GalaFLEX LITE Scaffold for reducing capsular contracture recurrence during breast implant revision surgery.
• Capsular contracture affects 10-20% of breast implant patients, with conventional revision techniques showing recurrence rates as high as 54%, highlighting the significant unmet medical need this trial addresses.
• The multi-center study will enroll 250 patients across 40 sites, randomizing subjects 2:1 to receive either the bioabsorbable P4HB scaffold or standard care without supportive matrix.
© Copyright 2025. All Rights Reserved by MedPath